参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征的临床观察

发布时间：2018-04-22 17:05

  本文选题：脑心综合征 + 参松养心胶囊　； 参考：《中国药房》2017年33期

【摘要】：目的:观察参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征(CCS)的疗效和安全性。方法:128例脑血管疾病并发CCS患者随机分为对照组(64例)和观察组(64例)。对照组患者给予常规治疗,观察组患者在对照组治疗的基础上给予参松养心胶囊1.6 g,每日3次,口服+依达拉奉注射液30 mg,加入0.9%氯化钠溶液250 mL中,静脉滴注,每日2次。两组疗程均为10 d。观察两组患者的临床疗效,治疗前后血清丙二醛(MDA)、超氧化物歧化酶(SOD)、儿茶酚胺[去甲肾上腺素(NE)、肾上腺素(E)、多巴胺(DA)]水平、肌钙蛋白I(cTnⅠ)、美国国立卫生研究院卒中量表评分(NIHSS),分析cTnⅠ水平与NIHSS评分相关性,并记录不良反应发生情况。结果:观察组患者神经系统、心电图总有效率均显著高于对照组,差异均有统计学意义(P0.05)。治疗前,两组患者血清MDA、SOD、NE、E、DA、cTnⅠ水平、NIHSS评分比较,差异均无统计学意义(P0.05)。治疗后,两组患者血清MDA、NE、E、DA、cTnⅠ水平、NIHSS评分均显著低于同组治疗前,且观察组显著低于对照组;两组患者血清SOD水平均显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P0.05)。cTnⅠ水平与NIHSS评分呈正相关(r=0.956,P=0.001)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:在常规治疗的基础上,参松养心胶囊联合依达拉奉可显著提高脑血管疾病并发CCS患者的疗效,改善儿茶酚胺、MDA、SOD水平,且未增加不良反应的发生。
[Abstract]:Objective: to observe the efficacy and safety of Shensong Yangxin capsule combined with Edaravone in the treatment of cerebrovascular diseases complicated with cerebral heart syndrome (CCS). Methods 128 cases of cerebrovascular disease complicated with CCS were randomly divided into control group (n = 64) and observation group (n = 64). The patients in the control group were given routine treatment, and the patients in the observation group were given Shensong Yangxin capsule 1.6 g, 3 times a day, 30 mg of Edaravone injection, added 0.9% sodium chloride solution 250 mL, intravenous drip twice a day. The course of treatment in both groups was 10 days. The clinical efficacy of the two groups was observed. The levels of serum malondialdehyde (MDA), superoxide dismutase (SOD), catecholamine (NE), epinephrine (epinephrine), dopamine (DA) before and after treatment were observed. Cardiac troponin (I(cTn 鈪，

本文编号：1788130